SCHEMBL18060908

SCHEMBL18060908

C=CC(=O)Nc1cccc(Sc2cc(OC)c(N3CCN(C)CC3)c(OC)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSC P53634 10/20 0.48
▸ EGFR P00533 6/20 0.48
▸ JAK3 P52333 6/20 0.48
▸ JAK2 O60674 3/20 0.48
▸ BLK P51451 3/20 0.48
▸ FLT3 P36888 2/20 0.48
▸ BTK Q06187 2/20 0.48
▸ ITK Q08881 2/20 0.48
▸ BMX P51813 2/20 0.48
▸ PLK4 O00444 1/20 0.48
▸ GAK O14976 1/20 0.48
▸ NUAK1 O60285 1/20 0.48
▸ PTK2 Q05397 1/20 0.48
▸ ERBB4 Q15303 1/20 0.48
▸ DCLK3 Q9C098 1/20 0.48
▸ NUAK2 Q9H093 1/20 0.48
▸ EML4 Q9HC35 1/20 0.48
▸ EIF2AK4 Q9P2K8 1/20 0.48
▸ ALK Q9UM73 1/20 0.48
▸ UCHL3 P15374 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18060720 0.87 UCHL3 (0.51) CTSCEGFRJAK3JAK2BLK
SCHEMBL12806084 0.82 UCHL3 (0.51) CTSCEGFRJAK3JAK2BLK
SCHEMBL18060691 0.81 CTSC (0.55) CTSCEGFRJAK3JAK2BLK
SCHEMBL18060985 0.80 UCHL3 (0.49) CTSCEGFRJAK3JAK2BLK
SCHEMBL18060663 0.76 CCNK (0.43) CTSCEGFRJAK3JAK2BLK
SCHEMBL12806022 0.76 EHMT2 (0.45) EGFRFLT3ITK
SCHEMBL12806017 0.74 JAK3 (0.45) CTSCEGFRJAK3JAK2BLK
SCHEMBL12806300 0.74 CTSC (0.56) CTSCEGFRUCHL3
SCHEMBL12806089 0.73 JAK3 (0.44) CTSCEGFRJAK3JAK2BLK
SCHEMBL12398357 0.72 DYRK1A (0.60) CTSCEGFRJAK3JAK2BLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3205647-B1 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2020-05-13 — — EP disclosed
EP-3205647-A2 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Memorial Sloan-Kettering Cancer Center (US) 2017-08-16 — — EP disclosed
EP-2467142-B1 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders SLOAN KETTERING INST CANCER (US) 2016-09-21 — — EP disclosed
Send feedback